Özcan Kara, P.Kara, T.Kaya, B.Kara Gedik, G.Sarı, O.2020-03-262020-03-262012Özcan Kara, P., Kara, T., Kaya, B., Kara Gedik, G., Sarı, O., (2012). The Value of FDG-PET/CT in the Post-Treatment Evaluation of Endometrial Carcinoma: A Comparison of PET/CT Findings with Conventional Imaging and CA 125 as a Tumour Marker. Revista Espanola De Medicina Nuclear E Imagen Molecular, 31(5), 257-260. DOI:10.1016/j.remn.2011.06.0012253-654Xhttps://dx.doi.org/10.1016/j.remn.2011.06.001https://hdl.handle.net/20.500.12395/28572Objectives: This retrospective study was designed to assess the value of positron emission tomography/computed tomography imaging (PET/CT) in the post-treatment evaluation of the patients with endometrial carcinoma and to compare PET/CT scan with conventional imaging (Cl) including computed tomography (CT), ultrasonography (US) and magnetic resonance imaging (MRI) and CA 125 with both 20 U/ml and 35 U/ml cut-off values. Materials and methods: A total of 31 patients who were treated for histopathologically proven endometrial adenocarcinoma, underwent PET/CT examination for restaging and suspected recurrence. Thirty five PET/CT studies were performed in 31 patients. Lesion status was determined on the basis of clinical follow-up including radiological imaging (follow-up CT scan) at least 6 months and response to therapy. Results: Of the 35 PET/CT studies, 13 (37%) studies were positive, whereas 22 (63%) of them were negative. On study-based analysis the overall sensitivity, specificity, accuracy for PET/CT imaging were 100%, 96% and 97%, respectively. The corresponding information for Cl were 46%, 87% and 74%, for CA 125 (cut off= 20 U/ml) measurement were 45%, 88% and 74%, and for CA 125 (cut off = 35 U/ml) measurement were 27%, 100% and 78%, respectively. On lesion-based analysis, PET/CT revealed only one false positive case. In none of 21 patients with negative 22 PET/CT studies, no subsequent clinical or radiological recurrences were observed with a follow-up of at least 6 months. Conclusion: FDG-PET/CT is found more useful modality than CI and CA 125 in the evaluation of post-treatment endometrial carcinoma patients, for suspected recurrence.en10.1016/j.remn.2011.06.001info:eu-repo/semantics/openAccessEndometrial CarcinomaFDG-PET/CTCA 125Article31525726023067527Q3WOS:000309022100004Q4